Concordance Rate between Clinicians and Watson for Oncology among Patients with Advanced Gastric Cancer: Early, Real-World Experience in Korea

Table 2

Univariate analysis of the concordance rate between WFO and the GMDT.

	Concordance (n = 27)	Discordance (n = 38)
Age	59.1 ± 12.3	62.0 ± 11.2	0.49
Sex			0.52
Male	17 (63.0%)	27 (71.1%)
Female	10 (37.0%)	11 (28.9%)
BMI	20.9 ± 3.6	21.6 ± 3.8	0.53
Chemotherapy			0.89
Adjuvant chemotherapy	14(51.9%)	19(50.0%)
Palliative chemotherapy	13(48.1%)	19(50.0%)
R resection			0.13
R0	19 (70.4%)	22 (57.9%)
R1	1 (3.7%)	1 (2.6%)
R2	2 (7.4%)	0 (0.0%)
HER2+	4	5	0.83
Stage			< 0.01
II	6 (22.2%)	15 (39.5%)
III	15 (55.6%)	4 (10.5%)
IV or recurrent	6 (22.2%)	19 (50.0%)
Performance			0.71
ECOG 0, 1	25 (92.6%)	34 (89.5%)
ECOG 2, 3	2 (7.4%)	4 (10.5%)

BMI, body mass index; HER2/neu, human epidermal growth factor receptor; ECOG,Eastern Cooperative Oncology Group.